Early Rheumatoid ArthritisPhase 3CONCERTONCT01185301
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
A Phase 3 study testing adalimumab and methotrexate in people with Early Rheumatoid Arthritis, run by AbbVie (prior sponsor, Abbott) at 68 sites in 10 countries.
Trial summary
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Early Rheumatoid Arthritis
- What is being tested?
- adalimumab and methotrexate
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 395 participants
- Where
- 68 sitesin 10 countries
- Study dates
- Oct 2010to Sep 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female subjects at least 18 years of age
- Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the 1987-revised American College of Rheumatology (ACR) classification criteria or the new ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and has a disease duration of less than 1 year from diagnosis by a licensed health care provider
- Subject must meet the following criteria:
- Disease Activity Score of C-reactive Protein (DAS28[CRP]) ≥ 3.2 (at the Baseline visit only)
- At least 6 swollen joints out of 66 assessed (at the Screening and Baseline visits)
- At least 8 tender joints out of 68 assessed (at the Screening and Baseline visits)
Show all 9Show fewer
- C-reactive protein (CRP) ≥ 1.5 mg/dL (at the Screening visit only), or erythrocyte sedimentation rate (ESR) ≥ 28 mm/1h (at the Screening and Baseline visits)
- Fulfill at least one of the following three criteria: Rheumatoid Factor (RF) positive, have at least 1 bony erosion, anti-cyclic citrullinated peptide (anti-CCP) antibody positive
- Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray (CXR), and a 12-lead electrocardiogram (ECG) performed during Screening
Who cannot join
- Subject has previous exposure to any systemic biologic therapy including adalimumab
- Subject has been previously treated with greater than 1 disease modifying antirheumatic drugs (DMARDs) or with methotrexate (MTX)
- Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study)
- Subject has chronic arthritis diagnosed before age 17 years
- History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or active Hepatitis C infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB)
- Hepatitis B virus: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the hepatitis B virus DNA (HBV DNA) polymerase chain reaction (PCR) qualitative test
- Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline Visit or oral anti-infectives within 14 days prior to the Baseline visit
- Female subject who is pregnant or breast-feeding or considering becoming pregnant
Trial locations and contacts
68 sites in 10 countries.
68 sites in 10 countries
United States30 sites
Site Reference ID/Investigator# 44284
Atlanta, Georgia, 30312
Site Reference ID/Investigator# 38971
Charleston, South Carolina, 29406
Site Reference ID/Investigator# 40651
Clifton, New Jersey, 07012
Site Reference ID/Investigator# 42202
Columbus, Ohio, 43213
Site Reference ID/Investigator# 39672
Covington, Louisiana, 70433
Site Reference ID/Investigator# 39643
Dallas, Texas, 75231
Site Reference ID/Investigator# 45325
Dallas, Texas, 75246
Site Reference ID/Investigator# 41423
Duncansville, Pennsylvania, 16635
Site Reference ID/Investigator# 41422
Freehold, New Jersey, 07728
Site Reference ID/Investigator# 38907
Gainesville, Georgia, 30501
Site Reference ID/Investigator# 40463
Greenville, North Carolina, 27834
Site Reference ID/Investigator# 38912
Hemet, California, 92543
Site Reference ID/Investigator# 52042
Houston, Texas, 77074
Site Reference ID/Investigator# 38973
Huntsville, Alabama, 35801
Site Reference ID/Investigator# 39666
Jackson, Tennessee, 38305
Site Reference ID/Investigator# 38909
Jacksonville, Florida, 32209
Site Reference ID/Investigator# 38972
Lawrenceville, Georgia, 30045
Site Reference ID/Investigator# 45323
Little Rock, Arkansas, 72205
Site Reference ID/Investigator# 41962
Mesa, Arizona, 85202
Site Reference ID/Investigator# 40422
Miami, Florida, 33169
Site Reference ID/Investigator# 44282
Norman, Oklahoma, 73069
Site Reference ID/Investigator# 42204
Omaha, Nebraska, 68114
Site Reference ID/Investigator# 39260
Phoenix, Arizona, 85031
Site Reference ID/Investigator# 39670
Rock Island, Illinois, 61201
Site Reference ID/Investigator# 38910
Sarasota, Florida, 34239
Site Reference ID/Investigator# 40602
Seattle, Washington, 98101
Site Reference ID/Investigator# 42282
Springfield, Illinois, 62704
Site Reference ID/Investigator# 41424
The Bronx, New York, 10467
Site Reference ID/Investigator# 39673
Victorville, California, 92395
Site Reference ID/Investigator# 38911
Wichita, Kansas, 67203
Czechia6 sites
Site Reference ID/Investigator# 44937
Brno, 63800
Site Reference ID/Investigator# 48962
České Budějovice, 37021
Site Reference ID/Investigator# 44939
Ostrava, 72200
Site Reference ID/Investigator# 44936
Prague, 128 50
Site Reference ID/Investigator# 44938
Uherské Hradiště, 686 01
Site Reference ID/Investigator# 48963
Zlín, 76001
Germany5 sites
Site Reference ID/Investigator# 44941
Berlin, 10117
Site Reference ID/Investigator# 44945
Buch, 13125
Site Reference ID/Investigator# 44942
Munich, 80336
Site Reference ID/Investigator# 44944
Ratingen, 40882
Site Reference ID/Investigator# 44943
Zerbst, 39261
Poland5 sites
Site Reference ID/Investigator# 44946
Bydgoszcz, 85168
Site Reference ID/Investigator# 44982
Lodz, 90-242
Site Reference ID/Investigator# 46584
Torun, 87-100
Site Reference ID/Investigator# 44984
Warsaw, 02-118
Site Reference ID/Investigator# 44983
Warsaw, 02-256
Puerto Rico5 sites
Site Reference ID/Investigator# 38975
Caguas, 00725
Site Reference ID/Investigator# 40122
San Juan, 00906-6312
Site Reference ID/Investigator# 39693
San Juan, 00936-5067
Site Reference ID/Investigator# 38916
San Juan, 00936-8344
Site Reference ID/Investigator# 39692
Vega Baja, 00693
Argentina4 sites
Site Reference ID/Investigator# 44924
Buenos Aires, C1055AAF
Site Reference ID/Investigator# 44926
Buenos Aires, C1425DTG
Site Reference ID/Investigator# 44925
Rosario, Santa Fe, S2000PBJ
Site Reference ID/Investigator# 47302
San Juan, J5402DIL
Belgium4 sites
Site Reference ID/Investigator# 44934
Brussels, 1200
Site Reference ID/Investigator# 44935
Genk, 3600
Site Reference ID/Investigator# 44933
Gilly, 6060
Site Reference ID/Investigator# 44932
Liège, 4000
Spain4 sites
Site Reference ID/Investigator# 44947
A Coruña, 15006
Site Reference ID/Investigator# 44987
Elche (Alicante), 03203
Site Reference ID/Investigator# 44948
Oviedo (Asturias), 33006
Site Reference ID/Investigator# 47782
Valencia, 46026
Austria3 sites
Site Reference ID/Investigator# 44928
Graz, 80360
Site Reference ID/Investigator# 44930
Vienna, 1090
Site Reference ID/Investigator# 44927
Vienna, 1100
Canada2 sites
Site Reference ID/Investigator# 43783
Edmonton, T5M 0H4
Site Reference ID/Investigator# 43782
Winnipeg, R3A 1M3
About this study
Official title: A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
- Conditions
- Early Rheumatoid Arthritis
- Being tested
- adalimumab, methotrexate
- Keywords
- Arthritis, Erosion, Humira, Adalimumab, Injection, Rheumatoid, Methotrexate
- Medical subject headings
- Arthritis, Rheumatoid, Arthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
adalimumabBiological
Also called Humira
Pre-filled syringe every other week
methotrexateDrug
weekly oral capsule dosing
| Study group | Role | What they receive |
|---|---|---|
| ADA + 2.5 mg MTX | Active comparator | 2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks Receives: Biological: adalimumab; Drug: methotrexate |
| ADA + 5 mg MTX | Active comparator | 5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks Receives: Biological: adalimumab; Drug: methotrexate |
| ADA + 10 mg MTX | Active comparator | 10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks Receives: Biological: adalimumab; Drug: methotrexate |
| ADA + 20 mg MTX | Active comparator | MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks Receives: Biological: adalimumab; Drug: methotrexate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26
Percentage of participants achieving low disease activity as defined by a clinical response (DAS28[CRP] < 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score >5.1 indicates high disease activity, a DAS28 score <3.2 indicates low disease activity, and a DAS28 score <2.6 indicates clinical remission.
Measured: Week 26
Secondary outcomes (12)
Percentage of Participants With DAS28(CRP) Remission at Week 26
Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was < 2.6 (DAS28[CRP] < 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.
Measured: Week 26
Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26
Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Disability Index of the Health Assessment Questionnaire
- Acute phase reactant value (C-reactive protein).
Measured: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26
Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Disability Index of the Health Assessment Questionnaire
- Acute phase reactant value (C-reactive protein).
Measured: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26
Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Disability Index of the Health Assessment Questionnaire
- Acute phase reactant value (C-reactive protein).
Measured: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26
Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Disability Index of the Health Assessment Questionnaire
- Acute phase reactant value (C-reactive protein).
Measured: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26
Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters:
- Physician global assessment of disease activity
- Patient global assessment of disease activity
- Patient assessment of pain
- Disability Index of the Health Assessment Questionnaire
- Acute phase reactant value (C-reactive protein).
Measured: Baseline, Week 26
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of < 0.5. Negative change from Baseline in the overall score indicates improvement.
Measured: Baseline, Week 26
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of < 0.5. Negative change from Baseline in the overall score indicates improvement.
Measured: Baseline, Week 26
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26
The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Measured: Baseline, Week 26
Percentage of Participants With No Radiographic Progression at Week 26
"No radiographic progression" was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Measured: Baseline, Week 26
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26
SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, > 3.4 to 11 = low disease activity, > 11 to 26 = moderate disease activity, and > 26 = high disease activity.
Measured: Week 26
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26
CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, > 2.8 to 10 = low disease activity, > 10 to 22 = moderate disease activity, and > 22 = high disease activity.
Measured: Week 26
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2010 (estimated)
- Study startOct 2010
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Early Rheumatoid ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 395 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Dawn Carlson, MD, Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01185301
- Sponsor's protocol ID
- M12-073
- Other IDs
- 2010-019514-24
- Acronym
- CONCERTO
- Status last verified
- Sep 2013
- First submitted
- 18 Aug 2010
- Last updated
- 15 Nov 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.
PubMed 29402521Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017.
PubMed 28955494Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.
PubMed 27338778
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)
- ClinicalTrials.gov ID
- NCT01185301
- Acronym / sponsor ID
- CONCERTO / M12-073
- Conditions
- Early Rheumatoid Arthritis
- Keywords
- Arthritis, Erosion, Humira, Adalimumab, Injection, Rheumatoid, Methotrexate
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 395 participants (actual)
- Lead sponsor
- AbbVie (prior sponsor, Abbott)Industry (pharma, biotech, devices)
- Study start
- Oct 2010
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 19 Aug 2010 (estimated)
- Results
- Posted 15 Nov 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| ADA + 2.5 mg MTX | Active comparator | Biological: adalimumab, Drug: methotrexate2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks |
| ADA + 5 mg MTX | Active comparator | Biological: adalimumab, Drug: methotrexate5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks |
| ADA + 10 mg MTX | Active comparator | Biological: adalimumab, Drug: methotrexate10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks |
| ADA + 20 mg MTX | Active comparator | Biological: adalimumab, Drug: methotrexateMTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Male and female subjects at least 18 years of age
- Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the 1987-revised American College of Rheumatology (ACR) classification criteria or the new ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and has a disease duration of less than 1 year from diagnosis by a licensed health care provider
- Subject must meet the following criteria:
- Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray (CXR), and a 12-lead electrocardiogram (ECG) performed during Screening
Key exclusion criteria (8 listed)
- Subject has previous exposure to any systemic biologic therapy including adalimumab
- Subject has been previously treated with greater than 1 disease modifying antirheumatic drugs (DMARDs) or with methotrexate (MTX)
- Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study)
- Subject has chronic arthritis diagnosed before age 17 years
- History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or active Hepatitis C infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| adalimumabAlso: HumiraPre-filled syringe every other week | Biological | ADA + 10 mg MTX, ADA + 2.5 mg MTX, ADA + 20 mg MTX, ADA + 5 mg MTX |
| methotrexateweekly oral capsule dosing | Drug | ADA + 10 mg MTX, ADA + 2.5 mg MTX, ADA + 20 mg MTX, ADA + 5 mg MTX |
Primary outcome
Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26
Time frame: Week 26
Percentage of participants achieving low disease activity as defined by a clinical response (DAS28[CRP] < 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score >5.1 indicates high disease activity, a DAS28 score <3.2 indicates low disease activity, and a DAS28 score <2.6 indicates clinical remission.
12 secondary outcomes
Percentage of Participants With DAS28(CRP) Remission at Week 26
Time frame: Week 26
Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26
Time frame: Baseline, Week 26
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26
Time frame: Baseline, Week 26
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With No Radiographic Progression at Week 26
Time frame: Baseline, Week 26
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26
Time frame: Week 26
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26
Time frame: Week 26
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 29402521Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002.
- Derived from this study: PubMed 28955494Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017.
- Derived from this study: PubMed 27338778Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23.
- Related InfoLink provided by the sponsor.
Related trials for Early Rheumatoid Arthritis
Not yet recruiting
Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
Rheumatoid Arthritis (RA
Active, not recruitingObservational study
Anatomical Shoulder Domelock System Study
Avascular Necrosis, Revision Surgery
Not yet recruitingObservational study
Atherosclerosis in Early Rheumatoid Arthritis Patients Using Atherogenic Index of the Plasma and Carotid Intima Media Thickness
Atheroscleroses, Rheumatoid Arthritis (RA
RecruitingObservational study
Early Rheumatoid Arthritis Lung Disease Study
Rheumatoid Arthritis
Active, not recruitingObservational study
Chronic Pain in Rheumatoid Arthritis
Arthritis, Rheumatoid, Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dawn Carlson, MD study director
AbbVie
68 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing adalimumab and methotrexate in people with Early Rheumatoid Arthritis, run by AbbVie (prior sponsor, Abbott) at 68 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 68 sites in United States, Czechia, Germany, Poland, Puerto Rico and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Nov 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26 (time frame: Week 26). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01185301, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2013; AzTrials last refreshed its copy on 6 Nov 2026.